LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stake Increased by Voya Investment Management LLC

Voya Investment Management LLC raised its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 8.5% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 45,043 shares of the medical instruments supplier's stock after purchasing an additional 3,522 shares during the period. Voya Investment Management LLC owned about 0.20% of LeMaitre Vascular worth $4,150,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in LMAT. Copeland Capital Management LLC grew its stake in LeMaitre Vascular by 0.7% in the 4th quarter. Copeland Capital Management LLC now owns 1,172,015 shares of the medical instruments supplier's stock valued at $107,990,000 after acquiring an additional 8,623 shares during the last quarter. Congress Asset Management Co. lifted its holdings in shares of LeMaitre Vascular by 1.8% in the fourth quarter. Congress Asset Management Co. now owns 722,325 shares of the medical instruments supplier's stock valued at $66,555,000 after purchasing an additional 13,009 shares in the last quarter. Geode Capital Management LLC grew its position in shares of LeMaitre Vascular by 1.4% in the fourth quarter. Geode Capital Management LLC now owns 550,260 shares of the medical instruments supplier's stock valued at $50,711,000 after purchasing an additional 7,737 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of LeMaitre Vascular by 0.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 284,779 shares of the medical instruments supplier's stock worth $26,240,000 after purchasing an additional 1,680 shares in the last quarter. Finally, Envestnet Asset Management Inc. raised its position in shares of LeMaitre Vascular by 7.0% during the 4th quarter. Envestnet Asset Management Inc. now owns 259,429 shares of the medical instruments supplier's stock worth $23,904,000 after purchasing an additional 16,886 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Trading Down 12.8 %

Shares of NASDAQ LMAT traded down $11.54 on Friday, reaching $78.70. 601,984 shares of the company traded hands, compared to its average volume of 162,901. The stock has a market capitalization of $1.78 billion, a PE ratio of 43.01, a P/E/G ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a fifty-two week low of $71.42 and a fifty-two week high of $109.58. The company has a 50 day moving average of $85.58 and a 200 day moving average of $93.34.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.02). The company had revenue of $59.87 million for the quarter, compared to analyst estimates of $57.61 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business's revenue for the quarter was up 12.0% on a year-over-year basis. During the same period last year, the company posted $0.44 EPS. As a group, research analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th will be given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 1.02%. The ex-dividend date of this dividend is Thursday, May 15th. LeMaitre Vascular's dividend payout ratio (DPR) is presently 41.24%.

Insiders Place Their Bets

In other news, insider Trent G. Kamke sold 2,009 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares of the company's stock, valued at $456,915.68. This represents a 26.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.79% of the stock is currently owned by insiders.

Analysts Set New Price Targets

LMAT has been the subject of several recent research reports. Oppenheimer downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Barrington Research cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Wells Fargo & Company assumed coverage on shares of LeMaitre Vascular in a report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 target price on the stock. Finally, Lake Street Capital lifted their price target on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Five investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $98.14.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.